Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Steve Push who wrote (49)	5/13/1999 6:11:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 360

Steve: >> I'm surprised this is the first issue that comes to mind when you begin analysis if our company << Just focusing on what's hot/hypable, and avoiding what's not. I'll focus on the database products when they start to attract more compliments than criticism.... exchange2000.com >> We purchase our spotting machine from Packard Instrument Company. We believe that they are not infringing anyone else's patents. << Does it only work with one chemistry? Are there patents that relate to deposition chemistries, to placing the oligonucleotide probes on the substrate, to the length of probes using a given chemistry, etc.? While we're off on this tangent, is there any need for GLGC to have a license to the Southern patent that AFFX recently discussed? >> Have you read our 1998 Annual Report or the business description in the 10K? I think those documents will help to put things in perspective for you. << I don't think so, but I read a lot of them and sometimes I forget stuff. I have read your prospectus dated 11/97, several times. I'm also a long-term shareholder in MLNM and hold a few shares of CRGN, so, overall, I feel that my perspective is decent. Would appreciate any help that you care to give relating to the questions listed above. Thanks in advance. Rick

To: Steve Push who wrote (49)	6/26/1999 11:18:00 AM
From: rkrw	Read Replies (3) \| Respond to of 360

Steve, As has become apparent, many big pharma's are fighting back against the royalty stacking game. In my opinion, the impact has been greatest at "tool" companies, of which I would consider Gene Logic to be a part of. I'm wondering how your past deals have been structured with regards to royalties. While you probably aren't permitted to say specifically, is low single digits a ballpark estimate? Your CEO stated on the last conference call that striking deals has been taking longer than anticipated and I am concerned that one reason may be differing opinions on fair royalties. I'd also like to know your opinion of your financial strength. How long will your current cash sustain your business and will you need to tap the markets for more cash any time soon? It would be a shame to dilute shareholders at such low prices. Its also a shame that with such weak currency, you are probably handcuffed in regards to making additional acquisitions and may yourself wind up as acquisition bait. Fair or not, the biotech sector does have a bit of Darwinism to it. Thanks